Sanofi invests 1.1 billion euros to construct a brand new manufacturing unit in France | EUROtoday

Would the Choose France summit, meant to advertise overseas investments on the nationwide territory, goal to develop with Franco-French “off programming”? While the seventh version of this annual excessive mass, which is being held on Monday May 13 on the Palace of Versailles, guarantees a document harvest of bulletins, the French laboratory Sanofi has simply unveiled, on the sidelines of the occasion, an funding of 1 .1 billion euros, as a way to strengthen its drug manufacturing capacities in France.

“We chose France a long time ago, and we continue to do so. This investment will contribute to our health sovereignty “, confides Audrey Derveloy, president of Sanofi France. The French flagship is thus doubling down on investments in health already disclosed within the framework of Choose France. The Elysée had in fact confirmed, on Sunday May 12, investments from the American laboratory Pfizer (500 million euros), the Anglo-Swedish AstraZeneca (365 million euros), the British GSK (140 million euros ) and the Swiss Novartis (28 million euros), for a total amount of just over 1 billion euros.

Around 91% of the envelope presented Monday by Sanofi, or 1 billion euros, will be devoted to the creation of a new factory on the group's century-old site located in Vitry-sur-Seine (Val-de-Marne), where the laboratory already produces several of its drugs, including its treatment against hypercholesterolemia, Praluent, the anticancer drug Sarclisa against multiple myeloma (a cancer of the bone marrow) or Kevzara, used in patients with rheumatoid arthritis.

A portfolio of twelve molecules with high potential

The future building will, once built, double the production capacity of monoclonal antibodies at the Vitry-sur-Seine site, with the aim of housing some of the group's next drugs currently under construction. development, for example “ in chronic bronchitis, asthma, multiple sclerosis or type 1 diabetes »details the company.

In December 2023, Sanofi highlighted a portfolio of twelve high-potential molecules, capable, once marketed, of each generating revenues of more than 1 billion euros. “We built this industrial project by looking at this portfolio, with the ambition of creating a continuum between the development of these drugs, which, for a large part of these molecules, is carried out partly in France, and their production,” explains Audrey Derveloy. Like the Sarclisa remedy, developed after which manufactured in Vitry-sur-Seine.

You have 48.58% of this text left to learn. The relaxation is reserved for subscribers.